Primary sclerosing cholangitis: Etiopathogenesis and clinical management

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 5, 2012, Pages 1683-1705

  Gupta, Asha ^a   Bowlus, Christopher L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Genetics; Immunology; Inflammatory Bowel Disease; Primary Sclerosing Cholangitis; Review; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; BILIRUBIN; BUDESONIDE; CARDIOLIPIN ANTIBODY; CERULOPLASMIN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ETANERCEPT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; METHOTREXATE; METRONIDAZOLE; MITOCHONDRION ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL CYTOPLASMIC ANTIBODY; PENICILLAMINE; PENTOXIFYLLINE; RIFAMPICIN; SMOOTH MUSCLE ANTIBODY; TACROLIMUS; THYROID PEROXIDASE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; URSODEOXYCHOLIC ACID;

AGE DISTRIBUTION; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; BILE; BILE DUCT CARCINOMA; BILE FLOW; BILIARY CIRRHOSIS; BILIRUBIN BLOOD LEVEL; CELL MIGRATION; CERULOPLASMIN BLOOD LEVEL; CHLAMYDIA; CHOLANGIOGRAPHY; CHOLESTASIS; CHROMOSOME 2Q; CLINICAL FEATURE; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE COURSE; END STAGE LIVER DISEASE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENVIRONMENTAL FACTOR; FLUORESCENCE IN SITU HYBRIDIZATION; GALLBLADDER DISEASE; GENE EXPRESSION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HAPLOTYPE; HELICOBACTER PYLORI; HEPATOJEJUNOSTOMY; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; ILEITIS; IMMUNORECEPTOR TYROSINE BASED INHIBITION MOTIF; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LIFE EXPECTANCY; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOCYTE; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; META ANALYSIS (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OSTEODYSTROPHY; OSTEOPOROSIS; PATHOGENESIS; PORTAL HYPERTENSION; POSITRON EMISSION TOMOGRAPHY; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROCTOCOLECTOMY; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; ROUX Y ANASTOMOSIS; SMOKING; SOCIAL STATUS; STEATORRHEA; TOTAL COLON RESECTION; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; GENETICS; IMMUNOLOGY; REVIEW; SCLEROSING CHOLANGITIS;

BACTERIA (MICROORGANISMS);

CHOLANGITIS, SCLEROSING; HUMANS;

EID: 84860856008     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: None     Document Type: Article

References (218)

1. YM Lee and MM Kaplan: Management of primary sclerosing cholangitis. Am J Gastroenterol, 973, 528-34 (2002)) (Pubitemid 34245877)
2. GR MacFaul and RW Chapman: Sclerosing cholangitis. Curr Opin Gastroenterol, 223, 288-93 (2006)) (Pubitemid 44090066)
3. P Portincasa, M Vacca, A Moschetta, M Petruzzelli, G Palasciano, KJ van Erpecum and GP van Berge-Henegouwen: Primary sclerosing cholangitis: updates in diagnosis and therapy. World J Gastroenterol, 111, 7-16 (2005)) (Pubitemid 40090127)
4. J Bargen: Complications and sequelae of chronic ulcerative colitis. Ann Intern Med, 3, 335-352 (1929))
5. P Kimmelstiel, HL Large, Jr. and HD Verner: Liver damage in ulcerative colitis. Am J Pathol, 282, 259-89 (1952))
6. K Bambha, WR Kim, J Talwalkar, H Torgerson, JT Benson, TM Therneau, EV Loftus, Jr., BP Yawn, ER Dickson and LJ Melton, 3rd: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology, 1255, 1364-9 (2003))
7. H Takikawa: Characteristics of primary sclerosing cholangitis in Japan. Hepatol Res, 37 Suppl 3, S470-3 (2007)) (Pubitemid 47570661)
8. CA Aoki, CL Bowlus and ME Gershwin: The immunobiology of primary sclerosing cholangitis. Autoimmun Rev, 43, 137-43 (2005)) (Pubitemid 40488742)
9. U Broome and A Bergquist: Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin Liver Dis, 261, 31-41 (2006)) (Pubitemid 43320725)
10. EV Loftus, Jr., GC Harewood, CG Loftus, WJ Tremaine, WS Harmsen, AR Zinsmeister, DA Jewell and WJ Sandborn: PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut, 541, 91-6 (2005)) (Pubitemid 40007225)
11. A Escorsell, A Pares, J Rodes, JA Solis-Herruzo, M Miras and E de la Morena: Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol, 215, 787-91 (1994)) (Pubitemid 24374145)
12. R Kochhar, MK Goenka, K Das, B Nagi, DK Bhasin, YK Chawla, K Vaiphei, K Singh and JB Dilawari: Primary sclerosing cholangitis: an experience from India. J Gastroenterol Hepatol, 115, 429-33 (1996)) (Pubitemid 26151918)
13. L Okolicsanyi, L Fabris, S Viaggi, N Carulli, M Podda and G Ricci: Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol, 87, 685-91 (1996)) (Pubitemid 26241599)
14. CN Bernstein, JF Blanchard, P Rawsthorne and N Yu: The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol, 964, 1116-22 (2001)) (Pubitemid 32319146)
15. KM Boberg, E Aadland, J Jahnsen, N Raknerud, M Stiris and H Bell: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol, 331, 99-103 (1998)) (Pubitemid 28114077)
16. GG Kaplan, KB Laupland, D Butzner, SJ Urbanski and SS Lee: The burden of large and small duct primary sclerosing cholangitis in adults and children: a populationbased analysis. Am J Gastroenterol, 1025, 1042-9 (2007))
17. JG Kingham, N Kochar and MB Gravenor: Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology, 1267, 1929-30 (2004)) (Pubitemid 38736362)
18. B Lindkvist, M Benito de Valle, B Gullberg and E Bjornsson: Incidence and prevalence of primary sclerosing cholangitis in a defined adult population in Sweden. Hepatology, 522, 571-7 (2010))
19. TR Card, M Solaymani-Dodaran and J West: Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol, 486, 939-44 (2008))
20. KJ Hurlburt, BJ McMahon, H Deubner, B Hsu-Trawinski, JL Williams and KV Kowdley: Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol, 979, 2402-7 (2002))
21. KM Boberg, A Bergquist, S Mitchell, A Pares, F Rosina, U Broome, R Chapman, O Fausa, T Egeland, G Rocca and E Schrumpf: Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. Scand J Gastroenterol, 3710, 1205-11 (2002)) (Pubitemid 35189610)
22. K Burak, P Angulo, TM Pasha, K Egan, J Petz and KD Lindor: Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol, 993, 523-6 (2004)) (Pubitemid 38524134)
23. C Penna, R Dozois, W Tremaine, W Sandborn, N LaRusso, C Schleck and D Ilstrup: Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis. Gut, 382, 234-9 (1996)) (Pubitemid 26046819)
24. TH Karlsen, J Hampe, K Wiencke, E Schrumpf, E Thorsby, BA Lie, U Broome, S Schreiber and KM Boberg: Genetic polymorphisms associated with inflammatory bowel disease do not confer risk for primary sclerosing cholangitis. Am J Gastroenterol, 1021, 115-21 (2007)) (Pubitemid 46072051)
25. S Saarinen, O Olerup and U Broome: Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis. Am J Gastroenterol, 9511, 3195-9 (2000))
26. JB Gross, Jr., J Ludwig, RH Wiesner, JT McCall and NF LaRusso: Abnormalities in tests of copper metabolism in primary sclerosing cholangitis. Gastroenterology, 892, 272-8 (1985)) (Pubitemid 15028582)
27. HH Rasmussen, J Fallingborg, PB Mortensen, L Freund, U Tage-Jensen, V Kruse and SN Rasmussen: Primary sclerosing cholangitis in patients with ulcerative colitis. Scand J Gastroenterol, 279, 732-6 (1992))
28. C Roozendaal, AW Van Milligen de Wit, EB Haagsma, G Horst, C Schwarze, HH Peter, JH Kleibeuker, JW Tervaert, PC Limburg and CG Kallenberg: Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: defined specificities may be associated with distinct clinical features. Am J Med, 1055, 393-9 (1998)) (Pubitemid 28536224)
29. R Tobias, JP Wright, RE Kottler, PC Bornman, SK Price, A Hatfield and IN Marks: Primary sclerosing cholangitis associated with inflammatory bowel disease in Cape Town, 1975 - 1981. S Afr Med J, 637, 229-35 (1983)) (Pubitemid 13110619)
30. SK Lo, KA Fleming and RW Chapman: Prevalence of anti-neutrophil antibody in primary sclerosing cholangitis and ulcerative colitis using an alkaline phosphatase technique. Gut, 3310, 1370-5 (1992))
31. S Lindgren, S Nilsson, L Nassberger, H Verbaan and J Wieslander: Anti-neutrophil cytoplasmic antibodies in patients with chronic liver diseases: prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. Swedish Internal Medicine Liver Club (SILK). J Gastroenterol Hepatol, 154, 437-42 (2000)) (Pubitemid 30262213)
32. AH Mulder, G Horst, EB Haagsma, PC Limburg, JH Kleibeuker and CG Kallenberg: Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology, 173, 411-7 (1993)) (Pubitemid 23072815)
33. F Seibold, D Slametschka, M Gregor and P Weber: Neutrophil autoantibodies: a genetic marker in primary sclerosing cholangitis and ulcerative colitis. Gastroenterology, 1072, 532-6 (1994)) (Pubitemid 24233330)
34. P Angulo, JB Peter, ME Gershwin, CK DeSotel, Y Shoenfeld, AE Ahmed and KD Lindor: Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol, 322, 182-7 (2000)) (Pubitemid 30093895)
35. S Cullen and R Chapman: Primary sclerosing cholangitis. Autoimmun Rev, 26, 305-12 (2003)) (Pubitemid 37211385)
36. L Zhang, JT Lewis, SC Abraham, TC Smyrk, S Leung, ST Chari, JJ Poterucha, CB Rosen, CM Lohse, JA Katzmann and TT Wu: IgG4+ plasma cell infiltrates in liver explants with primary sclerosing cholangitis. Am J Surg Pathol, 341, 88-94 (2010))
37. E Bjornsson, S Chari, M Silveira, A Gossard, N Takahashi, T Smyrk and K Lindor: Primary Sclerosing Cholangitis Associated with Elevated ImmunoglobulinG4: Clinical Characteristics and Response to Therapy. Am J Ther (2010))
38. M Dave, BJ Elmunzer, BA Dwamena and PD Higgins: Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology, 2562, 387-96 (2010))
39. C Weber, R Kuhlencordt, R Grotelueschen, U Wedegaertner, TL Ang, G Adam, N Soehendra and U Seitz: Magnetic resonance cholangiopancreatography in the diagnosis of primary sclerosing cholangitis. Endoscopy, 409, 739-45 (2008))
40. KW Burak, P Angulo and KD Lindor: Is there a role for liver biopsy in primary sclerosing cholangitis? Am J Gastroenterol, 985, 1155-8 (2003))
41. J Ludwig, SS Barham, NF LaRusso, LR Elveback, RH Wiesner and JT McCall: Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology, 16, 632-40 (1981)) (Pubitemid 12218457)
42. J Ludwig, ER Dickson and GS McDonald: Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol, 3792, 103-12 (1978)) (Pubitemid 8388145)
43. R Chapman, J Fevery, A Kalloo, DM Nagorney, KM Boberg, B Shneider and GJ Gores: Diagnosis and management of primary sclerosing cholangitis. Hepatology, 512, 660-78 (2010))
44. P Angulo, Y Maor-Kendler and KD Lindor: Small-duct primary sclerosing cholangitis: a long-term follow-up study. Hepatology, 356, 1494-500 (2002)) (Pubitemid 34966904)
45. E Bjornsson, R Olsson, A Bergquist, S Lindgren, B Braden, RW Chapman, KM Boberg and P Angulo: The natural history of small-duct primary sclerosing cholangitis. Gastroenterology, 1344, 975-80 (2008)) (Pubitemid 351451987)
46. GV Gregorio, B Portmann, J Karani, P Harrison, PT Donaldson, D Vergani and G Mieli-Vergani: Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology, 333, 544-53 (2001)) (Pubitemid 32185215)
47. HR van Buuren, HJE van Hoogstraten, T Terkivatan, SW Schalm and FP Vleggaar: High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol, 334, 543-8 (2000))
48. NF LaRusso, BL Shneider, D Black, GJ Gores, SP James, E Doo and JH Hoofnagle: Primary sclerosing cholangitis: summary of a workshop. Hepatology, 443, 746-64 (2006)) (Pubitemid 44433732)
49. N Chandok, MG Silveira and KD Lindor: Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis. Gastroenterol Hepatol (N Y), 62, 108-12 (2010))
50. R Olsson, H Glaumann, S Almer, U Broome, B Lebrun, A Bergquist, E Bjornsson, H Prytz, A Danielsson and S Lindgren: High prevalence of small duct primary sclerosing cholangitis among patients with overlapping autoimmune hepatitis and primary sclerosing cholangitis. Eur J Intern Med, 202, 190-6 (2009))
51. KM Boberg, T Egeland and E Schrumpf: Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand J Gastroenterol, 389, 991-5 (2003)) (Pubitemid 37158028)
52. U Broome, R Olsson, L Loof, G Bodemar, R Hultcrantz, A Danielsson, H Prytz, H Sandberg-Gertzen, S Wallerstedt and G Lindberg: Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut, 384, 610-5 (1996)) (Pubitemid 26111384)
53. JM Farrant, KM Hayllar, ML Wilkinson, J Karani, BC Portmann, D Westaby and R Williams: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology, 1006, 1710-7 (1991))
54. CY Ponsioen, SM Vrouenraets, W Prawirodirdjo, R Rajaram, EA Rauws, CJ Mulder, JB Reitsma, SH Heisterkamp and GN Tytgat: Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut, 514, 562-6 (2002))
55. WR Kim, TM Therneau, RH Wiesner, JJ Poterucha, JT Benson, M Malinchoc, NF LaRusso, KD Lindor and ER Dickson: A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc, 757, 688-94 (2000)) (Pubitemid 30441497)
56. CY Ponsioen, JB Reitsma, KM Boberg, L Aabakken, EA Rauws and E Schrumpf: Validation of a cholangiographic prognostic model in primary sclerosing cholangitis. Endoscopy, 429, 742-7 (2010))
57. JR Cangemi, RH Wiesner, SJ Beaver, J Ludwig, RL MacCarty, RR Dozois, AR Zinsmeister and NF LaRusso: Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis. Gastroenterology, 963, 790-4 (1989)) (Pubitemid 19057601)
58. TH Florin, N Pandeya and GL Radford-Smith: Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut, 537, 973-9 (2004)) (Pubitemid 38824155)
59. SA Mitchell, M Thyssen, TR Orchard, DP Jewell, KA Fleming and RW Chapman: Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study. Gut, 514, 567-73 (2002))
60. KJ van Erpecum, SJ Smits, PC van de Meeberg, FH Linn, FH Wolfhagen, GP vanBerge-Henegouwen and A Algra: Risk of primary sclerosing cholangitis is associated with nonsmoking behavior. Gastroenterology, 1105, 1503-6 (1996))
61. EV Loftus, Jr., WJ Sandborn, WJ Tremaine, DW Mahoney, AR Zinsmeister, KP Offord and LJ Melton, 3rd: Primary sclerosing cholangitis is associated with nonsmoking: a case-control study. Gastroenterology, 1105, 1496-502 (1996)) (Pubitemid 26134082)
62. RD Cohen and SB Hanauer: Protection from primary sclerosing cholangitis: smoke trails of just coattails? Gastroenterology, 1105, 1658-62 (1996)) (Pubitemid 26134106)
63. CL Bowlus, CS Li, TH Karlsen, BA Lie and C Selmi: Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl, 1611, 1324-30 (2010))
64. A Bergquist, G Lindberg, S Saarinen and U Broome: Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J Hepatol, 422, 252-6 (2005)) (Pubitemid 40143473)
65. A Bergquist, SM Montgomery, S Bahmanyar, R Olsson, A Danielsson, S Lindgren, H Prytz, R Hultcrantz, LA Loof, H Sandberg-Gertzen, S Almer, J Askling, A Ehlin and A Ekbom: Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol, 68, 939-43 (2008))
66. X Yang, SN Cullen, JH Li, RW Chapman and DP Jewell: Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol, 403, 375-9 (2004)) (Pubitemid 38230835)
67. CL Bowlus, TH Karlsen, U Broome, E Thorsby, M Vatn, E Schrumpf, BA Lie and KM Boberg: Analysis of MAdCAM-1 and ICAM-1 polymorphisms in 365 Scandinavian patients with primary sclerosing cholangitis. J Hepatol, 455, 704-10 (2006)) (Pubitemid 44466659)
68. TH Karlsen, A Franke, E Melum, A Kaser, JR Hov, T Balschun, BA Lie, A Bergquist, C Schramm, TJ Weismuller, D Gotthardt, C Rust, EE Philipp, T Fritz, L Henckaerts, RK Weersma, P Stokkers, CY Ponsioen, C Wijmenga, M Sterneck, M Nothnagel, J Hampe, A Teufel, H Runz, P Rosenstiel, A Stiehl, S Vermeire, U Beuers, MP Manns, E Schrumpf, KM Boberg and S Schreiber: Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology, 1383, 1102-11 (2010))
69. E Melum, A Franke, C Schramm, TJ Weismuller, DN Gotthardt, FA Offner, BD Juran, JK Laerdahl, V Labi, E Bjornsson, RK Weersma, L Henckaerts, A Teufel, C Rust, E Ellinghaus, T Balschun, KM Boberg, D Ellinghaus, A Bergquist, P Sauer, E Ryu, JR Hov, J Wedemeyer, B Lindkvist, M Wittig, RJ Porte, K Holm, C Gieger, HE Wichmann, P Stokkers, CY Ponsioen, H Runz, A Stiehl, C Wijmenga, M Sterneck, S Vermeire, U Beuers, A Villunger, E Schrumpf, KN Lazaridis, MP Manns, S Schreiber and TH Karlsen: Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet, 431, 17-9 (2011))
70. E Schrumpf, O Fausa, O Forre, JH Dobloug, S Ritland and E Thorsby: HLA antigens and immunoregulatory T cells in ulcerative colitis associated with hepatobiliary disease. Scand J Gastroenterol, 172, 187-91 (1982)) (Pubitemid 12185520)
71. RW Chapman, Z Varghese, R Gaul, G Patel, N Kokinon and S Sherlock: Association of primary sclerosing cholangitis with HLA-B8. Gut, 241, 38-41 (1983)) (Pubitemid 13170184)
72. JM Farrant, DG Doherty, PT Donaldson, RW Vaughan, KM Hayllar, KI Welsh, AL Eddleston and R Williams: Amino acid substitutions at position 38 of the DR beta polypeptide confer susceptibility to and protection from primary sclerosing cholangitis. Hepatology, 162, 390-5 (1992))
73. A Spurkland, S Saarinen, KM Boberg, S Mitchell, U Broome, L Caballeria, E Ciusani, R Chapman, G Ercilla, O Fausa, I Knutsen, A Pares, F Rosina, O Olerup, E Thorsby and E Schrumpf: HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens, 535, 459-69 (1999)) (Pubitemid 29224484)
74. TH Karlsen, KM Boberg, M Vatn, A Bergquist, J Hampe, E Schrumpf, E Thorsby, S Schreiber and BA Lie: Different HLA class II associations in ulcerative colitis patients with and without primary sclerosing cholangitis. Genes Immun, 83, 275-8 (2007)) (Pubitemid 46672059)
75. A Franke, T Balschun, TH Karlsen, J Sventoraityte, S Nikolaus, G Mayr, FS Domingues, M Albrecht, M Nothnagel, D Ellinghaus, C Sina, CM Onnie, RK Weersma, PC Stokkers, C Wijmenga, M Gazouli, D Strachan, WL McArdle, S Vermeire, P Rutgeerts, P Rosenstiel, M Krawczak, MH Vatn, CG Mathew and S Schreiber: Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet, 4011, 1319-23 (2008))
76. JR Oksenberg, LF Barcellos, BA Cree, SE Baranzini, TL Bugawan, O Khan, RR Lincoln, A Swerdlin, E Mignot, L Lin, D Goodin, HA Erlich, S Schmidt, G Thomson, DE Reich, MA Pericak-Vance, JL Haines and SL Hauser: Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet, 741, 160-7 (2004)) (Pubitemid 38085247)
77. K Wiencke, A Spurkland, E Schrumpf and KM Boberg: Primary sclerosing cholangitis is associated to an extended B8-DR3 haplotype including particular MICA and MICB alleles. Hepatology, 344 Pt 1, 625-30 (2001)) (Pubitemid 32927984)
78. S Norris, E Kondeatis, R Collins, J Satsangi, M Clare, R Chapman, H Stephens, P Harrison, R Vaughan and P Donaldson: Mapping MHC-encoded susceptibility and resistance in primary sclerosing cholangitis: the role of MICA polymorphism. Gastroenterology, 1206, 1475-82 (2001)) (Pubitemid 32322322)
79. W Bernal, M Moloney, J Underhill and PT Donaldson: Association of tumor necrosis factor polymorphism with primary sclerosing cholangitis. J Hepatol, 302, 237-41 (1999)) (Pubitemid 29071186)
80. SA Mitchell, J Grove, A Spurkland, KM Boberg, KA Fleming, CP Day, E Schrumpf and RW Chapman: Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut, 492, 288-94 (2001)) (Pubitemid 32675125)
81. TH Karlsen, KM Boberg, M Olsson, JY Sun, D Senitzer, A Bergquist, E Schrumpf, E Thorsby and BA Lie: Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol, 465, 899-906 (2007)) (Pubitemid 46529047)
82. SI Khakoo and M Carrington: KIR and disease: a model system or system of models? Immunol Rev, 214, 186-201 (2006)) (Pubitemid 44707911)
83. JR Hov, A Lleo, C Selmi, B Woldseth, L Fabris, M Strazzabosco, TH Karlsen and P Invernizzi: Genetic associations in Italian primary sclerosing cholangitis: heterogeneity across Europe defines a critical role for HLA-C. J Hepatol, 525, 712-7 (2010))
84. P Gaj, A Habior, M Mikula and J Ostrowski: Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients. BMC Med Genet, 9, 81 (2008))
85. MC Eike, GB Nordang, TH Karlsen, KM Boberg, MH Vatn, K Dahl-Jorgensen, KS Ronningen, G Joner, B Flato, A Bergquist, E Thorsby, O Forre, TK Kvien, DE Undlien and BA Lie: The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases. Ann Rheum Dis, 679, 1287-91 (2008))
86. A Franke, T Balschun, TH Karlsen, J Hedderich, S May, T Lu, D Schuldt, S Nikolaus, P Rosenstiel, M Krawczak and S Schreiber: Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat Genet, 406, 713-5 (2008)) (Pubitemid 351748866)
87. SA Fisher, M Tremelling, CA Anderson, R Gwilliam, S Bumpstead, NJ Prescott, ER Nimmo, D Massey, C Berzuini, C Johnson, JC Barrett, FR Cummings, H Drummond, CW Lees, CM Onnie, CE Hanson, K Blaszczyk, M Inouye, P Ewels, R Ravindrarajah, A Keniry, S Hunt, M Carter, N Watkins, W Ouwehand, CM Lewis, L Cardon, A Lobo, A Forbes, J Sanderson, DP Jewell, JC Mansfield, P Deloukas, CG Mathew, M Parkes and J Satsangi: Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat Genet, 406, 710-2 (2008)) (Pubitemid 351748865)
88. RK Weersma, PC Stokkers, I Cleynen, SC Wolfkamp, L Henckaerts, S Schreiber, G Dijkstra, A Franke, IM Nolte, P Rutgeerts, C Wijmenga and S Vermeire: Confirmation of multiple Crohn's disease susceptibility loci in a large Dutch-Belgian cohort. Am J Gastroenterol, 1043, 630-8 (2009))
89. V Keitel, M Donner, S Winandy, R Kubitz and D Haussinger: Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun, 3721, 78-84 (2008)) (Pubitemid 351778164)
90. Y Kawamata, R Fujii, M Hosoya, M Harada, H Yoshida, M Miwa, S Fukusumi, Y Habata, T Itoh, Y Shintani, S Hinuma, Y Fujisawa and M Fujino: A G protein-coupled receptor responsive to bile acids. J Biol Chem, 27811, 9435-40 (2003)) (Pubitemid 36800434)
91. V Keitel, K Cupisti, C Ullmer, WT Knoefel, R Kubitz and D Haussinger: The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology, 503, 861-70 (2009))
92. L Henckaerts, M Jaspers, W Van Steenbergen, L Vliegen, J Fevery, H Nuytten, T Roskams, P Rutgeerts, JJ Cassiman, S Vermeire and H Cuppens: Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis. J Hepatol, 501, 150-7 (2009))
93. PG Blanco, MM Zaman, O Junaidi, S Sheth, RK Yantiss, IA Nasser and SD Freedman: Induction of colitis in cftr-/- mice results in bile duct injury. Am J Physiol Gastrointest Liver Physiol, 2872, G491-6 (2004)) (Pubitemid 38955270)
94. S Sheth, JC Shea, MD Bishop, S Chopra, MM Regan, E Malmberg, C Walker, R Ricci, LC Tsui, PR Durie, J Zielenski and SD Freedman: Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet, 1133, 286-92 (2003)) (Pubitemid 36992289)
95. E Girodon, D Sternberg, O Chazouilleres, C Cazeneuve, D Huot, Y Calmus, R Poupon, M Goossens and C Housset: Cystic fibrosis transmembrane conductance regulator (CFTR) gene defects in patients with primary sclerosing cholangitis. J Hepatol, 372, 192-7 (2002)) (Pubitemid 34833080)
96. JR Hov, V Keitel, JK Laerdahl, L Spomer, E Ellinghaus, A ElSharawy, E Melum, KM Boberg, T Manke, T Balschun, C Schramm, A Bergquist, T Weismuller, D Gotthardt, C Rust, L Henckaerts, CM Onnie, RK Weersma, M Sterneck, A Teufel, H Runz, A Stiehl, CY Ponsioen, C Wijmenga, MH Vatn, PC Stokkers, S Vermeire, CG Mathew, BA Lie, U Beuers, MP Manns, S Schreiber, E Schrumpf, D Haussinger, A Franke and TH Karlsen: Mutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis. PLoS One, 58, e12403 (2010))
97. SW Chan, CJ Lim, L Chen, YF Chong, C Huang, H Song and W Hong: The hippo pathway in biological control and cancer development. J Cell Physiol (2010))
98. YQ Zhou, YQ Chen, JH Fisher and MH Wang: Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages. J Biol Chem, 27741, 38104-10 (2002))
99. M Raab, H Wang, Y Lu, X Smith, Z Wu, K Strebhardt, JE Ladbury and CE Rudd: T cell receptor "inside-out" pathway via signaling module SKAP1-RapL regulates T cell motility and interactions in lymph nodes. Immunity, 324, 541-56 (2010))
100. K Katagiri, T Katakai, Y Ebisuno, Y Ueda, T Okada and T Kinashi: Mst1 controls lymphocyte trafficking and interstitial motility within lymph nodes. EMBO J, 289, 1319-31 (2009))
101. P Goyette, C Lefebvre, A Ng, SR Brant, JH Cho, RH Duerr, MS Silverberg, KD Taylor, A Latiano, G Aumais, C Deslandres, G Jobin, V Annese, MJ Daly, RJ Xavier and JD Rioux: Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol, 12, 131-8 (2008))
102. ME Himmel, G Hardenberg, CA Piccirillo, TS Steiner and MK Levings: The role of T-regulatory cells and Tolllike receptors in the pathogenesis of human inflammatory bowel disease. Immunology, 1252, 145-53 (2008))
103. J Hampe, A Franke, P Rosenstiel, A Till, M Teuber, K Huse, M Albrecht, G Mayr, FM De La Vega, J Briggs, S Gunther, NJ Prescott, CM Onnie, R Hasler, B Sipos, UR Folsch, T Lengauer, M Platzer, CG Mathew, M Krawczak and S Schreiber: A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet, 392, 207-11 (2007)) (Pubitemid 46184351)
104. Y Ogura, DK Bonen, N Inohara, DL Nicolae, FF Chen, R Ramos, H Britton, T Moran, R Karaliuskas, RH Duerr, JP Achkar, SR Brant, TM Bayless, BS Kirschner, SB Hanauer, G Nunez and JH Cho: A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 4116837, 603-6 (2001)) (Pubitemid 32531409)
105. JP Hugot, M Chamaillard, H Zouali, S Lesage, JP Cezard, J Belaiche, S Almer, C Tysk, CA O'Morain, M Gassull, V Binder, Y Finkel, A Cortot, R Modigliani, P Laurent-Puig, C Gower-Rousseau, J Macry, JF Colombel, M Sahbatou and G Thomas: Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease. Nature, 4116837, 599-603 (2001)) (Pubitemid 32531408)
106. CA O'Mahony and JM Vierling: Etiopathogenesis of primary sclerosing cholangitis. Semin Liver Dis, 261, 3-21 (2006)) (Pubitemid 43320723)
107. E Seki and DA Brenner: Toll-like receptors and adaptor molecules in liver disease: update. Hepatology, 481, 322-35 (2008)) (Pubitemid 351975556)
108. A Karrar, U Broome, T Sodergren, M Jaksch, A Bergquist, M Bjornstedt and S Sumitran-Holgersson: Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology, 1324, 1504-14 (2007)) (Pubitemid 46627575)
109. RG Cameron, LM Blendis and MG Neuman: Accumulation of macrophages in primary sclerosing cholangitis. Clin Biochem, 343, 195-201 (2001)) (Pubitemid 32537671)
110. CT Wu, JP Eiserich, AA Ansari, RL Coppel, S Balasubramanian, CL Bowlus, ME Gershwin and J Van De Water: Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions. Hepatology, 384, 1018-25 (2003)) (Pubitemid 37221685)
111. K Tsuneyama, K Harada, N Kono, K Hiramatsu, Y Zen, Y Sudo, ME Gershwin, M Ikemoto, H Arai and Y Nakanuma: Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. J Hepatol, 352, 156-63 (2001)) (Pubitemid 32803469)
112. CH Hobson, TJ Butt, DM Ferry, J Hunter, VS Chadwick and MF Broom: Enterohepatic circulation of bacterial chemotactic peptide in rats with experimental colitis. Gastroenterology, 944, 1006-13 (1988))
113. RP Anderson, TJ Butt and VS Chadwick: Hepatobiliary excretion of bacterial formyl-methionyl peptides in rat. Structure activity studies. Dig Dis Sci, 372, 248-56 (1992))
114. CH Hobson, EC Roberts, MF Broom, DM Mellor, RM Sherriff and VS Chadwick: Radio-immunoassay for formyl methionyl leucyl phenylalanine. I. Development and application to assessment of chemotactic peptide production by enteric bacteria. J Gastroenterol Hepatol, 51, 32-7 (1990)) (Pubitemid 20133724)
115. S Yamada, M Ishii, N Kisara, R Nagatomi and T Toyota: Macrophages are essential for lymphocyte infiltration in formyl peptide-induced cholangitis in rat liver. Liver, 193, 253-8 (1999)) (Pubitemid 29261593)
116. S Yamada, M Ishii, LS Liang, T Yamamoto and T Toyota: Small duct cholangitis induced by N-formyl Lmethionine L-leucine L-tyrosine in rats. J Gastroenterol, 295, 631-6 (1994)) (Pubitemid 24308414)
117. SN Lichtman, RB Sartor, J Keku and JH Schwab: Hepatic inflammation in rats with experimental small intestinal bacterial overgrowth. Gastroenterology, 982, 414-23 (1990)) (Pubitemid 20037925)
118. SN Lichtman, J Keku, JH Schwab and RB Sartor: Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetracycline. Gastroenterology, 1002, 513-9 (1991))
119. SN Lichtman, EE Okoruwa, J Keku, JH Schwab and RB Sartor: Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth. J Clin Invest, 904, 1313-22 (1992))
120. E Bjornsson, A Cederborg, A Akvist, M Simren, PO Stotzer and I Bjarnason: Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. Scand J Gastroenterol, 409, 1090-4 (2005))
121. CY Ponsioen, J Defoer, FJ Ten Kate, GJ Weverling, GN Tytgat, Y Pannekoek and PM Wertheim-Dillen: A survey of infectious agents as risk factors for primary sclerosing cholangitis: are Chlamydia species involved? Eur J Gastroenterol Hepatol, 146, 641-8 (2002)) (Pubitemid 34666643)
122. AM Krasinskas, Y Yao, P Randhawa, MP Dore and AR Sepulveda: Helicobacter pylori may play a contributory role in the pathogenesis of primary sclerosing cholangitis. Dig Dis Sci, 529, 2265-70 (2007)) (Pubitemid 47246536)
123. SY Boomkens, S de Rave, RG Pot, HF Egberink, LC Penning, J Rothuizen, PE Zondervan and JG Kusters: The role of Helicobacter spp. in the pathogenesis of primary biliary cirrhosis and primary sclerosing cholangitis. FEMS Immunol Med Microbiol, 442, 221-5 (2005)) (Pubitemid 41373380)
124. RW Leong and JJ Sung: Review article: Helicobacter species and hepatobiliary diseases. Aliment Pharmacol Ther, 166, 1037-45 (2002)) (Pubitemid 34680745)
125. J Pohl, A Ring, W Stremmel and A Stiehl: The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol, 181, 69-74 (2006)) (Pubitemid 43004884)
126. CA Aoki, K Dawson, TP Kenny, ME Gershwin and CL Bowlus: Gene expression by PBMC in primary sclerosing cholangitis: evidence for dysregulation of immune mediated genes. Clin Dev Immunol, 132-4, 265-71 (2006)) (Pubitemid 44950042)
127. CM Milner, VA Higman and AJ Day: TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans, 34Pt 3, 446-50 (2006)) (Pubitemid 43954008)
128. R Chapman and S Cullen: Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol, 1421, 3350-9 (2008))
129. AJ Grant, PF Lalor, M Salmi, S Jalkanen and DH Adams: Homing of mucosal lymphocytes to the liver in the pathogenesis of hepatic complications of
130. B Eksteen, JR Mora, EL Haughton, NC Henderson, L Lee-Turner, EJ Villablanca, SM Curbishley, AI Aspinall, UH von Andrian and DH Adams: Gut homing receptors on CD8 T-cells ARE retinoic acid dependent and not maintained by Liver dendritic or stellate cells. Gastroenterology (2009))
131. B Eksteen, A Miles, SM Curbishley, C Tselepis, AJ Grant, LS Walker and DH Adams: Epithelial inflammation is associated with CCL28 production and the recruitment of regulatory T cells expressing CCR10. J Immunol, 1771, 593-603 (2006)) (Pubitemid 43939173)
132. B Eksteen, AJ Grant, A Miles, SM Curbishley, PF Lalor, SG Hubscher, M Briskin, M Salmon and DH Adams: Hepatic endothelial CCL25 mediates the recruitment of CCR9+ guthoming lymphocytes to the liver in primary sclerosing cholangitis. J Exp Med, 20011, 1511-7 (2004)) (Pubitemid 39657298)
133. AJ Grant, S Goddard, J Ahmed-Choudhury, G Reynolds, DG Jackson, M Briskin, L Wu, SG Hubscher and DH Adams: Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am J Pathol, 1604, 1445-55 (2002)) (Pubitemid 34411647)
134. AJ Grant, PF Lalor, SG Hubscher, M Briskin and DH Adams: MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology, 335, 1065-72 (2001)) (Pubitemid 32378204)
135. R Kurkijarvi, DH Adams, R Leino, T Mottonen, S Jalkanen and M Salmi: Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases. J Immunol, 1613, 1549-57 (1998)) (Pubitemid 28380589)
136. YH Oo, CJ Weston, PF Lalor, SM Curbishley, DR Withers, GM Reynolds, S Shetty, J Harki, JC Shaw, B Eksteen, SG Hubscher, LS Walker and DH Adams: Distinct roles for CCR4 and CXCR3 in the recruitment and positioning of regulatory T cells in the inflamed human liver. J Immunol, 1846, 2886-98 (2010))
137. YH Oo and DH Adams: The role of chemokines in the recruitment of lymphocytes to the liver. J Autoimmun, 341, 45-54 (2010))
138. AT Borchers, S Shimoda, C Bowlus, CL Keen and ME Gershwin: Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin Immunopathol, 313, 309-22 (2009))
139. KJ Hillan, KE Hagler, RN MacSween, AM Ryan, ME Renz, HH Chiu, RK Ferrier, GL Bird, AP Dhillon, LD Ferrell and S Fong: Expression of the mucosal vascular addressin, MAdCAM-1, in inflammatory liver disease. Liver, 196, 509-18 (1999)) (Pubitemid 30019065)
140. E Patsenker, Y Popov, F Stickel, A Jonczyk, SL Goodman and D Schuppan: Inhibition of integrin alphavbeta6 on cholangiocytes blocks transforming growth factor-beta activation and retards biliary fibrosis progression. Gastroenterology, 1352, 660-70 (2008))
141. M Trauner, P Fickert, E Halilbasic and T Moustafa: Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien Med Wochenschr, 15819-20, 542-8 (2008))
142. P Fickert, G Zollner, A Fuchsbichler, C Stumptner, AH Weiglein, F Lammert, HU Marschall, O Tsybrovskyy, K Zatloukal, H Denk and M Trauner: Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology, 1234, 1238-51 (2002))
143. Y Popov, E Patsenker, P Fickert, M Trauner and D Schuppan: Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. J Hepatol, 436, 1045-54 (2005)) (Pubitemid 41627991)
144. J Jahnel, P Fickert, C Langner, C Hogenauer, D Silbert, J Gumhold, A Fuchsbichler and M Trauner: Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Liver Int, 299, 1316-25 (2009))
145. P Fickert, A Fuchsbichler, M Wagner, G Zollner, A Kaser, H Tilg, R Krause, F Lammert, C Langner, K Zatloukal, HU Marschall, H Denk and M Trauner: Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology, 1271, 261-74 (2004)) (Pubitemid 38962293)
146. P Fickert, T Moustafa and M Trauner: Primary sclerosing cholangitis - the arteriosclerosis of the bile duct? Lipids Health Dis, 6, 3 (2007))
147. JF Gallegos-Orozco, EY C, N Wang, J Rakela, MR Charlton, GR Cutting and V Balan: Lack of association of common cystic fibrosis transmembrane conductance regulator gene mutations with primary sclerosing cholangitis. Am J Gastroenterol, 1004, 874-8 (2005)) (Pubitemid 40592382)
148. JM McGill, DM Williams and CM Hunt: Survey of cystic fibrosis transmembrane conductance regulator genotypes in primary sclerosing cholangitis. Dig Dis Sci, 413, 540-2 (1996)) (Pubitemid 26116410)
149. GU Denk, H Bikker, RH Lekanne Dit Deprez, V Terpstra, C van der Loos, U Beuers, C Rust and T Pusl: ABCB4 deficiency: A family saga of early onset cholelithiasis, sclerosing cholangitis and cirrhosis and a novel mutation in the ABCB4 gene. Hepatol Res, 409, 937-41 (2010))
150. R Poupon, L Arrive and O Rosmorduc: The cholangiographic features of severe forms of ABCB4/MDR3 deficiency-associated cholangiopathy in adults. Gastroenterol Clin Biol, 346-7, 380-7 (2010))
151. C Pauli-Magnus, R Kerb, K Fattinger, T Lang, B Anwald, GA Kullak-Ublick, U Beuers and PJ Meier: BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology, 393, 779-91 (2004)) (Pubitemid 38337658)
152. O Rosmorduc, B Hermelin, PY Boelle, RE Poupon, R Poupon and O Chazouilleres: ABCB4 gene mutations and primary sclerosing cholangitis. Gastroenterology, 1264, 1220-2; author reply 1222-3 (2004))
153. A Stiehl, G Rudolph, P Sauer and L Theilmann: Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment. J Hepatol, 233, 283-9 (1995))
154. TH Karlsen, BA Lie, K Frey Froslie, E Thorsby, U Broome, E Schrumpf and KM Boberg: Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology, 1313, 781-7 (2006)) (Pubitemid 44307062)
155. KD Lindor: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med, 33610, 691-5 (1997))
156. DS Pardi, EV Loftus, Jr., WK Kremers, J Keach and KD Lindor: Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology, 1244, 889-93 (2003)) (Pubitemid 36389790)
157. BY Tung, MJ Emond, RC Haggitt, MP Bronner, MB Kimmey, KV Kowdley and TA Brentnall: Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med, 1342, 89-95 (2001)) (Pubitemid 32096335)
158. J Shi, Z Li, X Zeng, Y Lin and WF Xie: Ursodeoxycholic acid in primary sclerosing cholangitis: meta-analysis of randomized controlled trials. Hepatol Res, 399, 865-73 (2009))
159. R Olsson, KM Boberg, OS de Muckadell, S Lindgren, R Hultcrantz, G Folvik, H Bell, M Gangsoy-Kristiansen, J Matre, A Rydning, O Wikman, A Danielsson, H Sandberg-Gertzen, KA Ung, A Eriksson, L Loof, H Prytz, HU Marschall and U Broome: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology, 1295, 1464-72 (2005)) (Pubitemid 41597389)
160. KD Lindor, KV Kowdley, VA Luketic, ME Harrison, T McCashland, AS Befeler, D Harnois, R Jorgensen, J Petz, J Keach, J Mooney, C Sargeant, J Braaten, T Bernard, D King, E Miceli, J Schmoll, T Hoskin, P Thapa and F Enders: Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 503, 808-14 (2009))
161. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol, 512, 237-67 (2009))
162. P Angulo, KP Batts, RA Jorgensen, NA LaRusso and KD Lindor: Oral budesonide in the treatment of primary sclerosing cholangitis. Am J Gastroenterol, 959, 2333-7 (2000))
163. TA Knox and MM Kaplan: A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology, 1062, 494-9 (1994)) (Pubitemid 24041229)
164. KD Lindor, RA Jorgensen, ML Anderson, GJ Gores, AF Hofmann and NF LaRusso: Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study. Am J Gastroenterol, 913, 511-5 (1996)) (Pubitemid 26083555)
165. RK Sterling, JJ Salvatori, VA Luketic, AJ Sanyal, AS Fulcher, RT Stravitz, MJ Contos, AS Mills and ML Shiffman: A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther, 209, 943-9 (2004)) (Pubitemid 39593275)
166. JA Talwalkar, P Angulo, JC Keach, JL Petz, RA Jorgensen and KD Lindor: Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. Am J Gastroenterol, 1002, 308-12 (2005)) (Pubitemid 40314514)
167. JA Talwalkar, AA Gossard, JC Keach, RA Jorgensen, JL Petz and RN Lindor: Tacrolimus for the treatment of primary sclerosing cholangitis. Liver Int, 274, 451-3 (2007)) (Pubitemid 46534566)
168. DH Van Thiel, P Carroll, K Abu-Elmagd, H Rodriguez-Rilo, W Irish, J McMichael and TE Starzl: Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol, 903, 455-9 (1995))
169. AE Bharucha, R Jorgensen, SN Lichtman, NF LaRusso and KD Lindor: A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. Am J Gastroenterol, 959, 2338-42 (2000))
170. MP Epstein and MM Kaplan: A pilot study of etanercept in the treatment of primary sclerosing cholangitis. Dig Dis Sci, 491, 1-4 (2004)) (Pubitemid 38183736)
171. NF LaRusso, RH Wiesner, J Ludwig, RL MacCarty, SJ Beaver and AR Zinsmeister: Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology, 954, 1036-42 (1988))
172. KD Lindor, RH Wiesner, LJ Colwell, B Steiner, S Beaver and NF LaRusso: The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. Am J Gastroenterol, 861, 57-61 (1991))
173. R Olsson, U Broome, A Danielsson, I Hagerstrand, G Jarnerot, L Loof, H Prytz, BO Ryden and S Wallerstedt: Colchicine treatment of primary sclerosing cholangitis. Gastroenterology, 1084, 1199-203 (1995))
174. P Angulo, AE Bharucha, RA Jorgensen, CK DeSotel, WJ Sandborn, NF Larusso and KD Lindor: Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci, 443, 602-7 (1999)) (Pubitemid 29137974)
175. FP Vleggaar, NA Van Ooteghem, HR Van Buuren and GP Van Berge Henegouwen: Cholestatic liver diseases: slow progress in understanding and treating slowly progressive disorders. Scand J Gastroenterol Suppl232, 86-92 (2000)) (Pubitemid 32142744)
176. MG Silveira, NJ Torok, AA Gossard, JC Keach, RA Jorgensen, JL Petz and KD Lindor: Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol, 1041, 83-8 (2009))
177. M Farkkila, AL Karvonen, H Nurmi, H Nuutinen, M Taavitsainen, P Pikkarainen and P Karkkainen: Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology, 406, 1379-86 (2004)) (Pubitemid 39657012)
178. MG Silveira and KD Lindor: Primary sclerosing cholangitis. Can J Gastroenterol, 228, 689-98 (2008))
179. NV Bergasa and EA Jones: The pruritus of cholestasis: evolving pathogenic concepts suggest new therapeutic options. Clin Liver Dis, 22, 391-405, x (1998))
180. J Browning, B Combes and MJ Mayo: Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol, 9812, 2736-41 (2003)) (Pubitemid 38020117)
181. EM Kuiper, KJ van Erpecum, U Beuers, BE Hansen, HB Thio, RA de Man, HL Janssen and HR van Buuren: The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: Results of a double-blind, randomized, placebo-controlled trial. Hepatology (2010))
182. NV Bergasa, DW Alling, TL Talbot, MG Swain, C Yurdaydin, ML Turner, JM Schmitt, EC Walker and EA Jones: Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial. Ann Intern Med, 1233, 161-7 (1995))
183. NV Bergasa, JM Schmitt, TL Talbot, DW Alling, MG Swain, ML Turner, JB Jenkins and EA Jones: Open-label trial of oral nalmefene therapy for the pruritus of cholestasis. Hepatology, 273, 679-84 (1998)) (Pubitemid 28103542)
184. MJ Mayo, I Handem, S Saldana, H Jacobe, Y Getachew and AJ Rush: Sertraline as a first-line treatment for cholestatic pruritus. Hepatology, 453, 666-74 (2007)) (Pubitemid 46450618)
185. S Khurana and P Singh: Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials. Liver Int, 268, 943-8 (2006)) (Pubitemid 44323412)
186. E Bjornsson, J Lindqvist-Ottosson, M Asztely and R Olsson: Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol, 993, 502-8 (2004)) (Pubitemid 38524130)
187. G Rudolph, D Gotthardt, P Kloters-Plachky, H Kulaksiz, D Rost and A Stiehl: Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. J Hepatol, 511, 149-55 (2009))
188. AR Baluyut, S Sherman, GA Lehman, H Hoen and N Chalasani: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc, 533, 308-12 (2001)) (Pubitemid 32207314)
189. M Gluck, NR Cantone, JJ Brandabur, DJ Patterson, JE Bredfeldt and RA Kozarek: A twenty-year experience with endoscopic therapy for symptomatic primary sclerosing cholangitis. J Clin Gastroenterol, 429, 1032-9 (2008))
190. SA Ahrendt: Surgical approaches to strictures in primary sclerosing cholangitis. J Gastrointest Surg, 123, 423-5 (2008))
191. S Tsai and TM Pawlik: Primary sclerosing cholangitis: the role of extrahepatic biliary resection. Adv Surg, 43, 175-88 (2009))
192. MM Claessen, FP Vleggaar, KM Tytgat, PD Siersema and HR van Buuren: High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol, 501, 158-64 (2009))
193. G Morris-Stiff, C Bhati, S Olliff, S Hubscher, B Gunson, D Mayer, D Mirza, J Buckels and SR Bramhall: Cholangiocarcinoma complicating primary sclerosing cholangitis: a 24-year experience. Dig Surg, 252, 126-32 (2008)) (Pubitemid 351748768)
194. J Fevery, C Verslype, G Lai, R Aerts and W Van Steenbergen: Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. Dig Dis Sci, 5211, 3123-35 (2007)) (Pubitemid 47512534)
195. E Melum, TH Karlsen, E Schrumpf, A Bergquist, E Thorsby, KM Boberg and BA Lie: Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology, 471, 90-6 (2008)) (Pubitemid 351171045)
196. NS Becker, JA Rodriguez, NR Barshes, CA O'Mahony, JA Goss and TA Aloia: Outcomes analysis for 280 patients with cholangiocarcinoma treated with liver transplantation over an 18-year period. J Gastrointest Surg, 121, 117-22 (2008))
197. DJ Rea, JK Heimbach, CB Rosen, MG Haddock, SR Alberts, WK Kremers, GJ Gores and DM Nagorney: Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg, 2423, 451-8; discussion 458-61 (2005))
198. CB Rosen, JK Heimbach and GJ Gores: Liver transplantation for cholangiocarcinoma. Transpl Int, 237, 692-7 (2010))
199. P Charatcharoenwitthaya, FB Enders, KC Halling and KD Lindor: Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. Hepatology, 484, 1106-17 (2008))
200. J Fevery, O Buchel, F Nevens, C Verslype, S Stroobants and W Van Steenbergen: Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol, 432, 358-60 (2005)) (Pubitemid 40956890)
201. CD Anderson, MH Rice, CW Pinson, WC Chapman, RS Chari and D Delbeke: Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg, 81, 90-7 (2004)) (Pubitemid 38117282)
202. H Prytz, S Keiding, E Bjornsson, U Broome, S Almer, M Castedal and OL Munk: Dynamic FDG-PET is useful for detection of cholangiocarcinoma in patients with PSC listed for liver transplantation. Hepatology, 446, 1572-80 (2006)) (Pubitemid 44953662)
203. G Vazquez-Elizondo, J Mucino-Bermejo and N Mendez-Sanchez: Gallbladder disease in patients with primary sclerosing cholangitis. Ann Hepatol, 72, 182-3 (2008)) (Pubitemid 351845535)
204. K Said, H Glaumann and A Bergquist: Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol, 484, 598-605 (2008))
205. DC Buckles, KD Lindor, NF Larusso, LM Petrovic and GJ Gores: In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol, 975, 1138-42 (2002)) (Pubitemid 34478111)
206. AH Kartheuser, RR Dozois, NF LaRusso, RH Wiesner, DM Ilstrup and CD Schleck: Comparison of surgical treatment of ulcerative colitis associated with primary sclerosing cholangitis: ileal pouch-anal anastomosis versus Brooke ileostomy. Mayo Clin Proc, 718, 748-56 (1996))
207. E Cholongitas, V Shusang, GV Papatheodoridis, L Marelli, P Manousou, N Rolando, D Patch, K Rolles, B Davidson and AK Burroughs: Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl, 142, 138-43 (2008)) (Pubitemid 351267268)
208. J Campsen, MA Zimmerman, JF Trotter, M Wachs, T Bak, T Steinberg and I Kam: Clinically recurrent primary sclerosing cholangitis following liver transplantation: a time course. Liver Transpl, 142, 181-5 (2008)) (Pubitemid 351267274)
209. J Alexander, JD Lord, MM Yeh, C Cuevas, R Bakthavatsalam and KV Kowdley: Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl, 142, 245-51 (2008)) (Pubitemid 351267284)
210. S Tamura, Y Sugawara, J Kaneko, Y Matsui, J Togashi and M Makuuchi: Recurrence of primary sclerosing cholangitis after living donor liver transplantation. Liver Int, 271, 86-94 (2007)) (Pubitemid 46139432)
211. U Oldakowska-Jedynak, M Nowak, K Mucha, B Foroncewicz, P Nyckowski, K Zieniewicz, B Ziarkiewicz-Wroblewska, W Patkowski, B Gornicka, A Paczkowska, B Michalowicz, T Pilecki, J Pawlak, M Krawczyk and L Paczek: Recurrence of primary sclerosing cholangitis in patients after liver transplantation. Transplant Proc, 381, 240-3 (2006))
212. B Brandsaeter, E Schrumpf, O Bentdal, K Brabrand, HJ Smith, A Abildgaard, OP Clausen and K Bjoro: Recurrent primary sclerosing cholangitis after liver transplantation: a magnetic resonance cholangiography study with analyses of predictive factors. Liver Transpl, 1111, 1361-9 (2005))
213. IW Graziadei: Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl, 87, 575-81 (2002)) (Pubitemid 34752702)
214. A Bergquist and U Broome: Clinical features in primary sclerosing cholangitis. Clin Liver Dis, 22, 283-301, viii (1998))
215. JH Helzberg, JM Petersen and JL Boyer: Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology, 926, 1869-75 (1987)) (Pubitemid 17072235)
216. MG Silveira and KD Lindor: Clinical features and management of primary sclerosing cholangitis. World J Gastroenterol, 1421, 3338-49 (2008))
217. JR Hov, KM Boberg and TH Karlsen: Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol, 1424, 3781-91 (2008))
218. D Zauli, E Schrumpf, C Crespi, F Cassani, O Fausa and E Aadland: An autoantibody profile in primary sclerosing cholangitis. J Hepatol, 51, 14-8 (1987)) (Pubitemid 17125241)